IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Metrics to compare | IGC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIGCPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.0x | −1.3x | −0.5x | |
PEG Ratio | −0.07 | 0.03 | 0.00 | |
Price/Book | 4.5x | 0.3x | 2.6x | |
Price / LTM Sales | 22.4x | 1.2x | 3.3x | |
Upside (Analyst Target) | - | 230.5% | 43.5% | |
Fair Value Upside | Unlock | 10.9% | 6.8% | Unlock |